-
1
-
-
60849128549
-
Monoclonal antibodies as innovative therapeutics
-
Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9(6), 423-430 (2008).
-
(2008)
Curr. Pharm. Biotechnol.
, vol.9
, Issue.6
, pp. 423-430
-
-
Reichert, J.M.1
-
2
-
-
0001313220
-
Thyroid function in nephrosis 1
-
Recant L, Riggs DS. Thyroid function in nephrosis 1. J. Clin. Invest. 31(8), 789-797 (1952).
-
(1952)
J. Clin. Invest.
, vol.31
, Issue.8
, pp. 789-797
-
-
Recant, L.1
Riggs, D.S.2
-
3
-
-
0001296463
-
The interaction of thyroid hormones and protein in biological fluids
-
discussion 202-168
-
Robbins J, Rall J. The interaction of thyroid hormones and protein in biological fluids. Recent Prog. Horm. Res. 13, 161-202; discussion 202-168 (1957).
-
(1957)
Recent Prog. Horm. Res.
, vol.13
, pp. 161-202
-
-
Robbins, J.1
Rall, J.2
-
4
-
-
0015699481
-
Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication
-
Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 14(2), 177-184 (1973).
-
(1973)
Epilepsia
, vol.14
, Issue.2
, pp. 177-184
-
-
Booker, H.E.1
Darcey, B.2
-
5
-
-
0021368529
-
Rationale for monitoring free drug levels
-
Levy RH, Moreland TA. Rationale for monitoring free drug levels. Clin. Pharmacokinetics 9(Suppl. 1), 1-9 (1984). (Pubitemid 14179495)
-
(1984)
Clinical Pharmacokinetics
, vol.9
, Issue.SUPPL. 1
, pp. 1-9
-
-
Levy, R.H.1
Moreland, T.A.2
-
6
-
-
77956341588
-
-
Hardman JG Limbird LE Molinoff PB Ruddon RW Gilman AG Eds 9th Edition McGraw-Hill Companies NY USA
-
Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (Eds).Goodman and Gilman's the Pharmacological Basis of Therapeutics (9th Edition).McGraw-Hill Companies, NY, USA (1996).
-
(1996)
Goodman and Gilmans the Pharmacological Basis of Therapeutics
-
-
-
7
-
-
0013531266
-
Theory of immunoassays
-
Diamandis EP Christopo TK Eds Elsevier Inc. San Diego CA USA
-
Christopoulos TK, Diamandis EP. Theory of immunoassays. In:Immunoassay. Diamandis EP, Christopo TK (Eds).Elsevier Inc., San Diego, CA, USA, 25-50 (1996).
-
(1996)
Immunoassay
, pp. 25-50
-
-
Christopoulos, T.K.1
Diamandis, E.P.2
-
8
-
-
46849108990
-
Introduction to immunoassay principles
-
3rd Edition Wild D Ed Elsevier Kidlington Oxford UK
-
Davies C. Introduction to immunoassay principles. In:The Immunoassay Handbook (3rd Edition). Wild D (Ed.) Elsevier, Kidlington, Oxford, UK, 3-40 (2005).
-
(2005)
Immunoassay Handbook
, pp. 3-40
-
-
Davies, C.1
-
9
-
-
0030853854
-
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
-
DOI 10.1016/S0091-6749(97)70202-1
-
Casale TB, Bernstein IL, Busse WW et al. Use of an anti-ige humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 100(1), 110-121 (1997). (Pubitemid 27328539)
-
(1997)
Journal of Allergy and Clinical Immunology
, vol.100
, Issue.1
, pp. 110-121
-
-
Casale, T.B.1
Bernstein, I.L.2
Busse, W.W.3
LaForce, C.F.4
Tinkelman, D.G.5
Stoltz, R.R.6
Dockhorn, R.J.7
Reimann, J.8
Su, J.Q.9
Fick Jr., R.B.10
Adelman, D.C.11
-
10
-
-
23844532353
-
Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy
-
DOI 10.1016/j.jim.2005.06.008, PII S0022175905001900
-
Hamilton RG, Marcotte GY, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J. Immunol. Methods 303(1-2), 81-91 (2005). (Pubitemid 41169948)
-
(2005)
Journal of Immunological Methods
, vol.303
, Issue.1-2
, pp. 81-91
-
-
Hamilton, R.G.1
Marcotte, G.V.2
Saini, S.S.3
-
11
-
-
66049094734
-
In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes
-
Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206(5), 1029-1036 (2009).
-
(2009)
J. Exp. Med.
, vol.206
, Issue.5
, pp. 1029-1036
-
-
Lachmann, H.J.1
Lowe, P.2
Felix, S.D.3
-
12
-
-
0035253739
-
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
-
Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncology 19(3), 843-850 (2001). (Pubitemid 32119100)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.3
, pp. 843-850
-
-
Gordon, M.S.1
Margolin, K.2
Talpaz, M.3
Sledge Jr., G.W.4
Holmgren, E.5
Benjamin, R.6
Stalter, S.7
Shak, S.8
Adelman, D.C.9
-
13
-
-
0034958819
-
Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis
-
DOI 10.1136/ard.60.7.660
-
Barrera P, Joosten LA, Den Broeder AA, Van De Putte LB, Van Riel PL, Van Den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor TNFa monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFa in patients with rheumatoid arthritis. Ann. Rheum. Dis. 60(7), 660-669 (2001). (Pubitemid 32588369)
-
(2001)
Annals of the Rheumatic Diseases
, vol.60
, Issue.7
, pp. 660-669
-
-
Barrera, P.1
Joosten, L.A.B.2
Den Broeder, A.A.3
Van De Putte, L.B.A.4
Van Riel, P.L.C.M.5
Van Den Berg, W.B.6
-
14
-
-
15244344037
-
On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach
-
DOI 10.1111/j.1742-7843.2005.pto960307.x
-
Meno-Tetang GML, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/ pharmacodynamic approach. Basic Clin. Pharmacol. Toxicol. 96(3), 182-192 (2005). (Pubitemid 40387994)
-
(2005)
Basic and Clinical Pharmacology and Toxicology
, vol.96
, Issue.3
, pp. 182-192
-
-
Meno-Tetang, G.M.L.1
Lowe, P.J.2
-
15
-
-
0033179534
-
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis
-
Charles P, Elliott MI, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNFa therapy in rheumatoid arthritis. J. Immunol. 163(3), 1521-1528 (1999). (Pubitemid 29352775)
-
(1999)
Journal of Immunology
, vol.163
, Issue.3
, pp. 1521-1528
-
-
Charles, P.1
Elliott, M.J.2
Davis, D.3
Potter, A.4
Kalden, J.R.5
Antoni, C.6
Breedveld, F.C.7
Smolen, J.S.8
Eberl, G.9
De Woody, K.10
Feldmann, M.11
Maini, R.N.12
-
16
-
-
0029411144
-
Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation
-
Gijbels K, Brocke S, Abrams JS, Steinman L. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol. Med. 1(7), 795-805 (1995). (Pubitemid 3013088)
-
(1995)
Molecular Medicine
, vol.1
, Issue.7
, pp. 795-805
-
-
Gijbels, K.1
Brocke, S.2
Abrams, J.S.3
Steinman, L.4
-
17
-
-
3142564395
-
Three new assays for rituximab based on its immunological activity or antigenic properties: Analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas
-
DOI 10.1016/j.jim.2004.03.012, PII S0022175904001206
-
Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289(1-2), 97-109 (2004). (Pubitemid 38900908)
-
(2004)
Journal of Immunological Methods
, vol.289
, Issue.1-2
, pp. 97-109
-
-
Beum, P.V.1
Kennedy, A.D.2
Taylor, R.P.3
-
18
-
-
79953662834
-
Comparison of a therapeutic target capture ligand-binding assay to an anti-idiotype capture sandwich ELISA
-
Spriggs F, Deng S, Soderstrom C, Aggarwal P, King L, Wang HF. Comparison of a therapeutic target capture ligand-binding assay to an anti-idiotype capture sandwich ELISA. AAPS J. 11(S1), 520 (2009).
-
(2009)
AAPS J.
, vol.11
, Issue.S1
, pp. 520
-
-
Spriggs, F.1
Deng, S.2
Soderstrom, C.3
Aggarwal, P.4
King, L.5
Wang, H.F.6
-
19
-
-
79953655047
-
Development of generic total assays for quantitation of therapeutic human IgG2 monoclonal antibodies in nonclinical species using ligand-binding assay
-
Guo J, King L, Wang HF. Development of generic total assays for quantitation of therapeutic human IgG2 monoclonal antibodies in nonclinical species using ligand-binding assay. AAPS J. 11(S1), 315 (2009).
-
(2009)
AAPS J.
, vol.11
, Issue.S1
, pp. 315
-
-
Guo, J.1
King, L.2
Wang, H.F.3
-
20
-
-
4344634877
-
Pharmacokinetic aspects of biotechnology products
-
DOI 10.1002/jps.20125
-
Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93(9), 2184-2204 (2004). (Pubitemid 39129617)
-
(2004)
Journal of Pharmaceutical Sciences
, vol.93
, Issue.9
, pp. 2184-2204
-
-
Tang, L.1
Persky, A.M.2
Hochhaus, G.3
Meibohm, B.4
-
21
-
-
54249138516
-
Monoclonal antibody pharmacokinetics and pharmacodynamics
-
Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84(5), 548-558 (2008).
-
(2008)
Clin. Pharmacol. Ther.
, vol.84
, Issue.5
, pp. 548-558
-
-
Wang, W.1
Wang, E.Q.2
Balthasar, J.P.3
-
23
-
-
32444438731
-
Elimination mechanisms of therapeutic monoclonal antibodies
-
DOI 10.1016/S1359-6446(05)03638-X, PII S135964460503638X
-
Tabrizi MA, Tseng C-Ml, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11(1-2), 81-88 (2006). (Pubitemid 43227856)
-
(2006)
Drug Discovery Today
, vol.11
, Issue.1-2
, pp. 81-88
-
-
Tabrizi, M.A.1
Tseng, C.-M.L.2
Roskos, L.K.3
-
24
-
-
0036882397
-
Protein ectodomain shedding
-
Arribas J, Borroto A. Protein ectodomain shedding. Chem. Rev. 102(12), 4627-4638 (2002).
-
(2002)
Chem. Rev.
, vol.102
, Issue.12
, pp. 4627-4638
-
-
Arribas, J.1
Borroto, A.2
-
25
-
-
20844454381
-
Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab
-
DOI 10.1038/nrd1752
-
Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4(6), 510-518 (2005). (Pubitemid 40861993)
-
(2005)
Nature Reviews Drug Discovery
, vol.4
, Issue.6
, pp. 510-518
-
-
Steinman, L.1
-
26
-
-
0033596831
-
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
-
Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52(5), 1072 (1999).
-
(1999)
Neurology
, vol.52
, Issue.5
, pp. 1072
-
-
Sheremata, W.A.1
Vollmer, T.L.2
Stone, L.A.3
Willmer-Hulme, A.J.4
Koller, M.5
-
27
-
-
33646431420
-
Shedding of lymphocyte function-associated antigen-1 LFA-1 in a human inflammatory response
-
Evans BJ, Mcdowall A, Taylor PC, Hogg N, Haskard DO, Landis RC. Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. Blood 107(9), 3593-3599 (2006).
-
(2006)
Blood
, vol.107
, Issue.9
, pp. 3593-3599
-
-
Evans, B.J.1
Mcdowall, A.2
Taylor, P.C.3
Hogg, N.4
Haskard, D.O.5
Landis, R.C.6
-
28
-
-
4243159775
-
In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells
-
DOI 10.1124/jpet.104.067611
-
Coffey GP, Stefanich E, Palmieri S et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J. Pharmacol. Exp. Ther. 310(3), 896-904 (2004). (Pubitemid 39108909)
-
(2004)
Journal of Pharmacology and Experimental Therapeutics
, vol.310
, Issue.3
, pp. 896-904
-
-
Coffey, G.P.1
Stefanich, E.2
Palmieri, S.3
Eckert, R.4
Padilla-Eagar, J.5
Fielder, P.J.6
Pippig, S.7
-
29
-
-
29644438538
-
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis
-
DOI 10.1177/0091270005283282
-
Joshi A, Bauer R, Kuebler P et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol. 46(1), 10-20 (2006). (Pubitemid 43021710)
-
(2006)
Journal of Clinical Pharmacology
, vol.46
, Issue.1
, pp. 10-20
-
-
Joshi, A.1
Bauer, R.2
Kuebler, P.3
White, M.4
Leddy, C.5
Compton, P.6
Garovoy, M.7
Kwon, P.8
Walicke, P.9
Dedrick, R.10
-
30
-
-
0028812791
-
Mechanisms of action and overview of OKT3
-
Norman DJ. Mechanisms of action and overview of OKT3. Ther. Drug Monit. 17(6), 615-620 (1995).
-
(1995)
Ther. Drug Monit.
, vol.17
, Issue.6
, pp. 615-620
-
-
Norman, D.J.1
-
31
-
-
0028236071
-
Variations in serum OKT3 concentration based upon age sex transplanted organ treatment regimen, and anti-OKT3 antibody status
-
Schroeder TJ, Michael AT, First MR et al. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther. Drug Monit. 16(4), (1994).
-
(1994)
Ther. Drug Monit.
, vol.16
, pp. 4
-
-
Schroeder, T.J.1
Michael, A.T.2
First, M.R.3
-
32
-
-
0036137093
-
Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen
-
DOI 10.1124/jpet.300.1.346
-
Meijer RT, Koopmans RP, Ten Berge IJM, Schellekens PTA. Pharmacokinetics of murine antihuman CD3 antibodies in man are determined by the disappearance of target antigen. J. Pharmacol. Exp. Ther. 300(1), 346-353 (2002). (Pubitemid 34028546)
-
(2002)
Journal of Pharmacology and Experimental Therapeutics
, vol.300
, Issue.1
, pp. 346-353
-
-
Meijer, R.T.1
Koopmans, R.P.2
Ten Berge, I.J.M.3
Schellekens, P.T.A.4
-
33
-
-
0034254362
-
The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score
-
Legrand O, Perrot J-Y, Baudard M et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 96(3), 870-877 (2000). (Pubitemid 30616850)
-
(2000)
Blood
, vol.96
, Issue.3
, pp. 870-877
-
-
Legrand, O.1
Perrot, J.-Y.2
Baudard, M.3
Cordier, A.4
Lautier, R.5
Simonin, G.6
Zittoun, R.7
Casadevall, N.8
Marie, J.-P.9
-
34
-
-
0034770328
-
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
-
DOI 10.1177/00912700122012751
-
Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41(11), 1206-1214 (2001). (Pubitemid 32983219)
-
(2001)
Journal of Clinical Pharmacology
, vol.41
, Issue.11
, pp. 1206-1214
-
-
Dowell, J.A.1
Korth-Bradley, J.2
Liu, H.3
King, S.P.4
Berger, M.S.5
-
35
-
-
4544350808
-
Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
-
DOI 10.1517/14712598.4.9.1445
-
Damle NK. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin. Biol. Ther. 4(9), 1445-1452 (2004). (Pubitemid 39222977)
-
(2004)
Expert Opinion on Biological Therapy
, vol.4
, Issue.9
, pp. 1445-1452
-
-
Damle, N.K.1
-
36
-
-
58149331196
-
High shed antigen levels within tumors: An additional barrier to immunoconjugate therapy
-
Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 14(24), 7981-7986 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.24
, pp. 7981-7986
-
-
Zhang, Y.1
Pastan, I.2
-
37
-
-
0023101978
-
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
-
Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69(2), 584-591 (1987). (Pubitemid 17022032)
-
(1987)
Blood
, vol.69
, Issue.2
, pp. 584-591
-
-
Press, O.W.1
Appelbaum, F.2
Ledbetter, J.A.3
-
38
-
-
0038446696
-
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
-
DOI 10.1182/blood-2002-06-1639
-
Manshouri T, Do K-A, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7), 2507-2513 (2003). (Pubitemid 36857605)
-
(2003)
Blood
, vol.101
, Issue.7
, pp. 2507-2513
-
-
Manshouri, T.1
Do, K.-A.2
Wang, X.3
Giles, F.J.4
O'Brien, S.M.5
Saffer, H.6
Thomas, D.7
Jilani, I.8
Kantarjian, H.M.9
Keating, M.J.10
Albitar, M.11
-
39
-
-
10744232932
-
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
-
DOI 10.1046/j.1365-2141.2003.04683.x
-
Giles FJ, Vose JM, Do K-A et al. Circulating CD20 and CD52 in patients with non- Hodgkin's lymphoma or Hodgkin's disease. Br. J. Haematol. 123(5), 850-857 (2003). (Pubitemid 37533297)
-
(2003)
British Journal of Haematology
, vol.123
, Issue.5
, pp. 850-857
-
-
Giles, F.J.1
Vose, J.M.2
Do, K.-A.3
Johnson, M.M.4
Manshouri, T.5
Bociek, G.6
Bierman, P.J.7
O'Brien, S.M.8
Keating, M.J.9
Kantarjian, H.M.10
Armitage, J.O.11
Albitar, M.12
-
40
-
-
1842368507
-
IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
-
Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-c2b8 (rituximab) anti- CD20 monoclonal antibody therapy in patients with relapsed low-grade non- Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997). (Pubitemid 27392702)
-
(1997)
Blood
, vol.90
, Issue.6
, pp. 2188-2195
-
-
Maloney, D.G.1
Grillo-Lopez, A.J.2
White, C.A.3
Bodkin, D.4
Schilder, R.J.5
Neidhart, J.A.6
Janakiraman, N.7
Foon, K.A.8
Liles, T.-M.9
Dallaire, B.K.10
Wey, K.11
Royston, I.12
Davis, T.13
Levy, R.14
-
41
-
-
4944220440
-
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
-
DOI 10.1182/blood-2004-05-1733
-
Cragg MS, Bayne MB, Tutt AL et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104(8), 2540-2542 (2004). (Pubitemid 39331858)
-
(2004)
Blood
, vol.104
, Issue.8
, pp. 2540-2542
-
-
Cragg, M.S.1
Bayne, M.B.2
Tutt, A.L.3
French, R.R.4
Beers, S.5
Glennie, M.J.6
Illidge, T.M.7
-
42
-
-
75749148026
-
Clinical response pharmacokinetics development of human anti-chimeric antibodies and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
-
10.1136/ard.2009.109041 Epub ahead of print
-
Thurlings RM, Teng O, Vos K et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. DOI:10.1136/ard.2009.109041 (2009) (Epub ahead of print).
-
(2009)
Ann. Rheum. Dis.
-
-
Thurlings, R.M.1
Teng, O.2
Vos, K.3
-
43
-
-
34547850227
-
Evaluation of a peptide ELISA for the detection of rituximab in serum
-
DOI 10.1016/j.jim.2007.06.011, PII S0022175907002049
-
Blasco H, Lalmanach G, Godat E et al. Evaluation of a peptide elisa for the detection of rituximab in serum. J. Immunol. Methods 325(1-2), 127-139 (2007). (Pubitemid 47243660)
-
(2007)
Journal of Immunological Methods
, vol.325
, Issue.1-2
, pp. 127-139
-
-
Blasco, H.1
Lalmanach, G.2
Godat, E.3
Maurel, M.C.4
Canepa, S.5
Belghazi, M.6
Paintaud, G.7
Degenne, D.8
Chatelut, E.9
Cartron, G.10
Le Guellec, C.11
-
44
-
-
33847257777
-
Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
-
DOI 10.1016/j.critrevonc.2006.09.004, PII S1040842806002009
-
Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit. Rev. Oncology/Hematology 62(1), 43-52 (2007). (Pubitemid 46330791)
-
(2007)
Critical Reviews in Oncology/Hematology
, vol.62
, Issue.1
, pp. 43-52
-
-
Cartron, G.1
Blasco, H.2
Paintaud, G.3
Watier, H.4
Le Guellec, C.5
-
45
-
-
1842791537
-
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
-
DOI 10.1016/j.ctrv.2003.10.003
-
Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev. 30(3), 255-268 (2004). (Pubitemid 38477271)
-
(2004)
Cancer Treatment Reviews
, vol.30
, Issue.3
, pp. 255-268
-
-
Thomas, S.M.1
Grandis, J.R.2
-
46
-
-
19244366949
-
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
-
Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody c225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000). (Pubitemid 30106623)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.4
, pp. 904-914
-
-
Baselga, J.1
Pfister, D.2
Cooper, M.R.3
Cohen, R.4
Burtness, B.5
Bos, M.6
D'Andrea, G.7
Seidman, A.8
Norton, L.9
Gunnett, K.10
Falcey, J.11
Anderson, V.12
Waksal, H.13
Mendelsohn, J.14
-
47
-
-
33847411438
-
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing
-
DOI 10.1158/1078-0432.CCR-06-1542
-
Fracasso PM, Burris H, Arquette MA et al. A Phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin. Cancer Res. 13(3), 986-993 (2007). (Pubitemid 46340377)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.3
, pp. 986-993
-
-
Fracasso, P.M.1
Burris III, H.2
Arquette, M.A.3
Govindan, R.4
Gao, F.5
Wright, L.P.6
Goodner, S.A.7
Greco, F.A.8
Jones, S.F.9
Willcut, N.10
Chodkiewicz, C.11
Pathak, A.12
Springett, G.M.13
Simon, G.R.14
Sullivan, D.M.15
Marcelpoil, R.16
Mayfield, S.D.17
Mauro, D.18
Garrett, C.R.19
-
48
-
-
23644457632
-
Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma
-
DOI 10.1016/j.ejca.2005.04.029, PII S0959804905004302
-
Delbaldo C, Pierga J-Y, Dieras V et al. Pharmacokinetic profile of cetuximab (erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer 41(12), 1739-1745 (2005). (Pubitemid 41132635)
-
(2005)
European Journal of Cancer
, vol.41
, Issue.12
, pp. 1739-1745
-
-
Delbaldo, C.1
Pierga, J.-Y.2
Dieras, V.3
Faivre, S.4
Laurence, V.5
Vedovato, J.-C.6
Bonnay, M.7
Mueser, M.8
Nolting, A.9
Kovar, A.10
Raymond, E.11
-
49
-
-
39149088612
-
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck
-
DOI 10.1177/0091270007313393
-
Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J. Clin. Pharmacol. 48(3), 267-278 (2008). (Pubitemid 351257778)
-
(2008)
Journal of Clinical Pharmacology
, vol.48
, Issue.3
, pp. 267-278
-
-
Dirks, N.L.1
Nolting, A.2
Kovar, A.3
Meibohm, B.4
-
50
-
-
4143050397
-
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
-
DOI 10.1200/JCO.2004.11.061
-
Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22(15), 3003-3015 (2004). (Pubitemid 41103711)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.15
, pp. 3003-3015
-
-
Rowinsky, E.K.1
Schwartz, G.H.2
Gollob, J.A.3
Thompson, J.A.4
Vogelzang, N.J.5
Figlin, R.6
Bukowski, R.7
Haas, N.8
Lockbaum, P.9
Li, Y.-P.10
Arends, R.11
Foon, K.A.12
Schwab, G.13
Dutcher, J.14
-
51
-
-
1842410784
-
Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients
-
DOI 10.1002/(SICI)1097-0142(19970515) 79:10<1879::AID-CNCR6>3.0. CO;2-B
-
Choi J-H, Oh JY, Ryu SK et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79(10), 1879-1883 (1997). (Pubitemid 27200369)
-
(1997)
Cancer
, vol.79
, Issue.10
, pp. 1879-1883
-
-
Choi, J.-H.1
Oh, J.Y.2
Ryu, S.K.3
Kim, S.J.4
Lee, N.Y.5
Kim, Y.S.6
Yi, S.Y.7
Shim, K.S.8
Han, W.S.9
-
52
-
-
30544438325
-
Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
-
DOI 10.1016/j.ejca.2005.08.036, PII S0959804905009408
-
Hudelist G, Köstler WJ, Gschwantler- Kaulich D et al. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur. J. Cancer 42(2), 186-192 (2006). (Pubitemid 43083488)
-
(2006)
European Journal of Cancer
, vol.42
, Issue.2
, pp. 186-192
-
-
Hudelist, G.1
Kostler, W.J.2
Gschwantler-Kaulich, D.3
Czerwenka, K.4
Kubista, E.5
Muller, R.6
Helmy, S.7
Manavi, M.8
Zielinski, C.C.9
Singer, C.F.10
-
53
-
-
70349658281
-
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab
-
Cézé N, Ternant D, Piller F et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther. Drug Monit. 31(5), 597-601 (2009).
-
(2009)
Ther. Drug Monit
, vol.31
, Issue.5
, pp. 597-601
-
-
Cézé, N.1
Ternant, D.2
Piller, F.3
-
54
-
-
0031903646
-
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
-
Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16(8), 2659-2671 (1998). (Pubitemid 28363029)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.8
, pp. 2659-2671
-
-
Pegram, M.D.1
Lipton, A.2
Hayes, D.F.3
Weber, B.L.4
Baselga, J.M.5
Tripathy, D.6
Baly, D.7
Baughman, S.A.8
Twaddell, T.9
Glaspy, J.A.10
Slamon, D.J.11
-
55
-
-
63749132329
-
Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer
-
Lennon S, Barton C, Banken L et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J. Clin. Oncol. 27(10), 1685-1693 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.10
, pp. 1685-1693
-
-
Lennon, S.1
Barton, C.2
Banken, L.3
-
56
-
-
0032713216
-
Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
Tokuda Y, Watanabe T, Omuro Y et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br. J. Cancer 81(8), 1419-1425 (1999).
-
(1999)
Br. J. Cancer
, vol.81
, Issue.8
, pp. 1419-1425
-
-
Tokuda, Y.1
Watanabe, T.2
Omuro, Y.3
-
57
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3), 737-744 (1996).
-
(1996)
J. Clin. Oncol.
, vol.14
, Issue.3
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn J3
-
58
-
-
13844315800
-
Development and validation of ELISA for Herceptin detection in human serum
-
DOI 10.1016/j.jim.2004.09.012, PII S0022175904003291
-
Maple L, Lathrop R, Bozich S et al. Development and validation of ELISA for herceptin detection in human serum. J. Immunol. Methods 295(1-2), 169-182 (2004). (Pubitemid 41057779)
-
(2004)
Journal of Immunological Methods
, vol.295
, Issue.1-2
, pp. 169-182
-
-
Maple, L.1
Lathrop, R.2
Bozich, S.3
Harman, W.4
Tacey, R.5
Kelley, M.6
Danilkovitch-Miagkova, A.7
-
59
-
-
77955530237
-
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation
-
Sageshima J, Ciancio G, Chen L, Burke GW. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics 3, 319-336 (2009).
-
(2009)
Biologics
, vol.3
, pp. 319-336
-
-
Sageshima, J.1
Ciancio, G.2
Chen, L.3
Burke, G.W.4
-
60
-
-
0028786730
-
Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay
-
Fayer BE, Soni PP, Binger MH, Mould DR, Satoh H. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. J. Immunol. Methods 186(1), 47-54 (1995).
-
(1995)
J. Immunol. Methods
, vol.186
, Issue.1
, pp. 47-54
-
-
Fayer, B.E.1
Soni, P.P.2
Binger, M.H.3
Mould, D.R.4
Satoh, H.5
-
61
-
-
38149076482
-
Serum soluble interleukin 2 receptor a in human cancer of adults and children: A review
-
Bien E, Balcerska A. Serum soluble interleukin 2 receptor a in human cancer of adults and children: a review. Biomarkers 13(1), 1-26 (2008).
-
(2008)
Biomarkers
, vol.13
, Issue.1
, pp. 1-26
-
-
Bien, E.1
Balcerska, A.2
-
62
-
-
0028226496
-
Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias
-
Engelhard D, Nagler A, Singer R, Barak V. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias. Leuk Lymphoma 12(3-4), 273-280 (1994). (Pubitemid 24077177)
-
(1994)
Leukemia and Lymphoma
, vol.12
, Issue.3-4
, pp. 273-280
-
-
Engelhard, D.1
Nagler, A.2
Singer, R.3
Barak, V.4
-
63
-
-
17644382690
-
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
-
DOI 10.1136/ard.2004.030452
-
Wolbink GJ, Voskuyl AE, Lems WF et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(5), 704-707 (2005). (Pubitemid 40559296)
-
(2005)
Annals of the Rheumatic Diseases
, vol.64
, Issue.5
, pp. 704-707
-
-
Wolbink, G.J.1
Voskuyl, A.E.2
Lems, W.F.3
De Groot, E.4
Nurmohamed, M.T.5
Tak, P.P.6
Dijkmans, B.A.C.7
Aarden, L.8
-
64
-
-
33847167546
-
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
-
DOI 10.1177/0091270006298188
-
Zhou H, Jang H, Fleischmann RM et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNFa monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47(3), 383-396 (2007). (Pubitemid 46294717)
-
(2007)
Journal of Clinical Pharmacology
, vol.47
, Issue.3
, pp. 383-396
-
-
Zhou, H.1
Jang, H.2
Fleischmann, R.M.3
Bouman-Thio, E.4
Xu, Z.5
Marini, J.C.6
Pendley, C.7
Jiao, Q.8
Shankar, G.9
Marciniak, S.J.10
Cohen, S.B.11
Rahman, M.U.12
Baker, D.13
Mascelli, M.A.14
Davis, H.M.15
Everitt, D.E.16
-
65
-
-
0028607153
-
Targeting TNFa for the therapy of rheumatoid arthritis
-
Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. Targeting TNFa for the therapy of rheumatoid arthritis. Clin. Exp. Rheumatol. 12(Suppl. 11), S63-S66 (1994).
-
(1994)
Clin. Exp. Rheumatol.
, vol.12
, Issue.11
-
-
Maini, R.N.1
Elliott, M.2
Brennan, F.M.3
Williams, R.O.4
Feldmann, M.5
-
66
-
-
33748193708
-
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab
-
DOI 10.1097/01.ftd.0000189901.08684.4b, PII 0000769120060400000004
-
Ternant D, Mulleman D, Degenne D et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther. Drug Monitor. 28(2), 169-174 (2006). (Pubitemid 44314944)
-
(2006)
Therapeutic Drug Monitoring
, vol.28
, Issue.2
, pp. 169-174
-
-
Ternant, D.1
Mulleman, D.2
Degenne, D.3
Willot, S.4
Guillaumin, J.-M.5
Watier, H.6
Goupille, P.7
Paintaud, G.8
-
67
-
-
0038721588
-
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
-
DOI 10.1016/S0149-2918(03)80164-9
-
Weisman MH, Moreland LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 25(6), 1700-1721 (2003). (Pubitemid 36801943)
-
(2003)
Clinical Therapeutics
, vol.25
, Issue.6
, pp. 1700-1721
-
-
Weisman, M.H.1
Moreland, L.W.2
Furst, D.E.3
Weinblatt, M.E.4
Keystone, E.C.5
Paulus, H.E.6
Teoh, L.S.7
Velagapudi, R.B.8
Noertersheuser, P.A.9
Granneman, G.R.10
Fischkoff, S.A.11
Chartash, E.K.12
-
68
-
-
65649090964
-
Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study
-
Loyet KM, Deng R, Liang W-C, Wu Y, Lowman HB, Deforge LE. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Methods 345(1-2), 17-28 (2009).
-
(2009)
J. Immunol. Methods
, vol.345
, Issue.1-2
, pp. 17-28
-
-
Loyet, K.M.1
Deng, R.2
Liang, W.-C.3
Wu, Y.4
Lowman, H.B.5
Deforge, L.E.6
-
69
-
-
0023445565
-
Radioimmunoassay of tumor necrosis factor in serum
-
Teppo AM, Maury CP. Radioimmunoassay of tumor necrosis factor in serum. Clin. Chem. 33(11), 2024-2027 (1987).
-
(1987)
Clin. Chem.
, vol.33
, Issue.11
, pp. 2024-2027
-
-
Teppo, A.M.1
Maury, C.P.2
-
70
-
-
67349158643
-
Widely varying TNF - A levels in patients with myasthenia gravis
-
Lee JS, Joo IS, Seok JI. Widely varying TNF-a levels in patients with myasthenia gravis. Neurol. Sci. 30(3), 259-262 (2009).
-
(2009)
Neurol. Sci.
, vol.30
, Issue.3
, pp. 259-262
-
-
Lee, J.S.1
Joo, I.S.2
Seok, J.I.3
-
71
-
-
0036188219
-
Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis
-
DOI 10.1002/art.10177
-
Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheumatism 46(3), 654-662 (2002). (Pubitemid 34214248)
-
(2002)
Arthritis and Rheumatism
, vol.46
, Issue.3
, pp. 654-662
-
-
Straub, R.H.1
Paimela, L.2
Peltomaa, R.3
Scholmerich, J.4
Leirisalo-Repo, M.5
-
72
-
-
34247344172
-
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
-
DOI 10.1111/j.1365-2125.2006.02803.x
-
Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63(5), 548-561 (2007). (Pubitemid 46632569)
-
(2007)
British Journal of Clinical Pharmacology
, vol.63
, Issue.5
, pp. 548-561
-
-
Hayashi, N.1
Tsukamoto, Y.2
Sallas, W.M.3
Lowe, P.J.4
-
73
-
-
67650938578
-
Relationship between omalizumab pharmacokinetics IgE pharmacodynamics and symptoms in patients with severe persistent allergic IgE-mediated asthma
-
Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br. J. Clin. Pharmacol. 68(1), 61-76 (2009).
-
(2009)
Br. J. Clin. Pharmacol.
, vol.68
, Issue.1
, pp. 61-76
-
-
Lowe, P.J.1
Tannenbaum, S.2
Gautier, A.3
Jimenez, P.4
-
74
-
-
0030440886
-
Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys
-
Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 279(2), 1000-1008 (1996). (Pubitemid 27166878)
-
(1996)
Journal of Pharmacology and Experimental Therapeutics
, vol.279
, Issue.2
, pp. 1000-1008
-
-
Fox, J.A.1
Hotaling, T.E.2
Struble, C.3
Ruppel, J.4
Bates, D.J.5
Schoenhoff, M.B.6
-
75
-
-
79953660097
-
Case studies: Free vs total ligand-binding PK assays to support monoclonal antibody therapeutic development
-
Presented at: Seattle WA USA
-
Yang J. Case studies: 'free' vs. 'total' ligand-binding PK assays to support monoclonal antibody therapeutic development. Presented at: 2009 AAPS National Biotechnology Conference. Seattle, WA, USA (2009).
-
(2009)
2009 AAPS National Biotechnology Conference
-
-
Yang, J.1
-
76
-
-
58149129505
-
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations
-
e103
-
Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J. Allergy Clin. Immunol. 123(1), 107-113. e103 (2009).
-
(2009)
J. Allergy Clin. Immunol.
, vol.123
, Issue.1
, pp. 107-113
-
-
Slavin, R.G.1
Ferioli, C.2
Tannenbaum, S.J.3
Martin, C.4
Blogg, M.5
Lowe, P.J.6
-
77
-
-
33745771388
-
Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing
-
DOI 10.1097/01.iae.0000225354.92444.7a, PII 0000698220060500000004
-
Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. RETINA 26(5), 519-522 (2006). (Pubitemid 44620392)
-
(2006)
Retina
, vol.26
, Issue.5
, pp. 519-522
-
-
Bakri, S.J.1
Snyder, M.R.2
Pulido, J.S.3
McCannel, C.A.4
Weiss, W.T.5
Singh, R.J.6
-
78
-
-
34247400587
-
Pharmacokinetics of intravitreal bevacizumab avastin
-
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin).Ophthalmology 114(5), 855-859 (2007).
-
(2007)
Ophthalmology
, vol.114
, Issue.5
, pp. 855-859
-
-
Bakri, S.J.1
Snyder, M.R.2
Reid, J.M.3
Pulido, J.S.4
Singh, R.J.5
-
79
-
-
49749124673
-
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
-
Lu J, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 62(5), 779-786 (2008).
-
(2008)
Cancer Chemother. Pharmacol.
, vol.62
, Issue.5
, pp. 779-786
-
-
Lu, J.1
Bruno, R.2
Eppler, S.3
Novotny, W.4
Lum, B.5
Gaudreault, J.6
-
80
-
-
33749647304
-
Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients
-
DOI 10.1097/01.iae.0000233327.68433.02, PII 0000698220061000000003
-
Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S.Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26(8), 871-876 (2006). (Pubitemid 44547438)
-
(2006)
Retina
, vol.26
, Issue.8
, pp. 871-876
-
-
Beer, P.M.1
Wong, S.J.2
Hammad, A.M.3
Falk, N.S.4
O'Malley, M.R.5
Khan, S.6
-
81
-
-
0032944081
-
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
-
DOI 10.1002/(SICI)1097-0142(19990101) 85:1<178::AID-CNCR25>3.0. CO;2-7
-
Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85(1), 178-187 (1999). (Pubitemid 29031373)
-
(1999)
Cancer
, vol.85
, Issue.1
, pp. 178-187
-
-
Kraft, A.1
Weindel, K.2
Ochs, A.3
Marth, C.4
Zmija, J.5
Schumacher, P.6
Unger, C.7
Marme, D.8
Gastl, G.9
-
82
-
-
66649102432
-
Use of canakinumab in the cryopyrin-associated periodic syndrome
-
Lachmann HJ, Kone-Paut I, Kuemmerle- Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. New Engl.J. Med. 360(23), 2416-2425 (2009).
-
(2009)
New Engl.J. Med.
, vol.360
, Issue.23
, pp. 2416-2425
-
-
Lachmann, H.J.1
Kone-Paut, I.2
Kuemmerle-Deschner, J.B.3
-
83
-
-
10744228553
-
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
-
DOI 10.1056/NEJMoa031688
-
Hillmen P, Hall C, Marsh JCW et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl.J. Med. 350(6), 552-559 (2004). (Pubitemid 38160785)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.6
, pp. 552-559
-
-
Hillmen, P.1
Hall, C.2
Marsh, J.C.W.3
Elebute, M.4
Bombara, M.P.5
Petro, B.E.6
Cullen, M.J.7
Richards, S.J.8
Rollins, S.A.9
Mojcik, C.F.10
Rother, R.P.11
-
84
-
-
0030441149
-
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.
-
DOI 10.1016/S0161-5890(96)00078-8, PII S0161589096000788
-
Thomas TC, Rollins SA, Rother RP et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33(17-18), 1389-1401 (1996). (Pubitemid 27196373)
-
(1996)
Molecular Immunology
, vol.33
, Issue.17-18
, pp. 1389-1401
-
-
Thomas, T.C.1
Rollins, S.A.2
Rother, R.P.3
Giannoni, M.A.4
Hartman, S.L.5
Elliott, E.A.6
Nye, S.H.7
Matis, L.A.8
Squinto, S.P.9
Evans, M.J.10
-
85
-
-
0032479161
-
C5 convertase of the alternative pathway of complement
-
Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. J. Biol. Chem. 273(27), 16828-16835 (1998).
-
(1998)
J. Biol. Chem.
, vol.273
, Issue.27
, pp. 16828-16835
-
-
Rawal, N.1
Pangburn, M.K.2
-
86
-
-
6844242330
-
Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
-
DOI 10.1097/00006454-199802000-00006
-
Siva Subramanian KN, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17(2), 110-115 (1998). (Pubitemid 28096007)
-
(1998)
Pediatric Infectious Disease Journal
, vol.17
, Issue.2
, pp. 110-115
-
-
Subramanian, K.N.S.1
Weisman, L.E.2
Rhodes, T.3
Ariagno, R.4
Sanchez, P.J.5
Steichen, J.6
Givner, L.B.7
Jennings, T.L.8
Top Jr., F.H.9
Carlin, D.10
Connor, E.11
-
87
-
-
0033922969
-
90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
-
Wiseman GA, White CA, Stabin M et al. Phase I/II 90y-zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-y2b8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur. J. Nucl. Med. 27(7), 766-777 (2000). (Pubitemid 30456759)
-
(2000)
European Journal of Nuclear Medicine
, vol.27
, Issue.7
, pp. 766-777
-
-
Wiseman, G.A.1
White, C.A.2
Stabin, M.3
Dunn, W.L.4
Erwin, W.5
Dahlbom, M.6
Raubitschek, A.7
Karvelis, K.8
Schultheiss, T.9
Witzig, T.E.10
Belanger, R.11
Spies, S.12
Silverman, D.H.S.13
Berlfein, J.R.14
Ding, E.15
Grillo-Lopez, A.J.16
-
88
-
-
0034329326
-
A phase I/ II trial of iodine-131-tositumomab anti-CD20 etoposide cyclophosphamide and autologous stem cell transplantation for relapsed b-cell lymphomas
-
Press OW, Eary JF, Gooley T et al. A phase I/ II trial of iodine-131-tositumomab (anti- CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed b-cell lymphomas. Blood 96(9), 2934-2942 (2000).
-
(2000)
Blood
, vol.96
, Issue.9
, pp. 2934-2942
-
-
Press, O.W.1
Eary, J.F.2
Gooley, T.3
-
89
-
-
0036470439
-
Pharmacokinetics of CAMPATH-1H: Assay development and validation
-
DOI 10.1016/S0022-1759(01)00556-7, PII S0022175901005567
-
Rebello P, Hale G. Pharmacokinetics of campath-1h: assay development and validation. J. Immunol. Methods 260(1-2), 285-302 (2002). (Pubitemid 34132893)
-
(2002)
Journal of Immunological Methods
, vol.260
, Issue.1-2
, pp. 285-302
-
-
Rebello, P.1
Hale, G.2
-
90
-
-
4744371910
-
Alemtuzumab: Validation of a sensitive and simple enzyme-linked immunosorbent assay
-
DOI 10.1016/j.leukres.2004.04.003, PII S0145212604001274
-
Jilani I, Keating M, Giles FJ, O'brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leukemia Res. 28(12), 1255-1262 (2004). (Pubitemid 39314404)
-
(2004)
Leukemia Research
, vol.28
, Issue.12
, pp. 1255-1262
-
-
Jilani, I.1
Keating, M.2
Giles, F.J.3
O'Brien, S.4
Kantarjian, H.M.5
Albitar, M.6
-
91
-
-
4143070373
-
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
-
DOI 10.1002/cncr.20477
-
Albitar M, Do K-A, Johnson MM et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101(5), 999-1008 (2004). (Pubitemid 39100434)
-
(2004)
Cancer
, vol.101
, Issue.5
, pp. 999-1008
-
-
Albitar, M.1
Do, K.-A.2
Johnson, M.M.3
Giles, F.J.4
Jilani, I.5
O'Brien, S.6
Cortes, J.7
Thomas, D.8
Rassenti, L.Z.9
Kipps, T.J.10
Kantarjian, H.M.11
Keating, M.12
-
92
-
-
0037323185
-
Robustness into advanced age of atopy-specific mechanisms in atopy-prone families
-
Jackola DR, Pierson-Mullany LK, Daniels LR, Corazalla E, Rosenberg A, Blumenthal MN. Robustness into advanced age of atopy-specific mechanisms in atopy-prone families. J. Gerontol. A Biol. Sci. Med. Sci. 58(2), B99-B107 (2003).
-
(2003)
J. Gerontol. A Biol. Sci. Med. Sci.
, vol.58
, Issue.2
-
-
Jackola, D.R.1
Pierson-Mullany, L.K.2
Daniels, L.R.3
Corazalla, E.4
Rosenberg, A.5
Blumenthal, M.N.6
|